AvantGen And Tanabe Research Laboratories Expand Collaboration For Therapeutic Antibody Discovery

January 4, 2018

SAN DIEGO, CALIFORNIA – AvantGen today announced the successful completion of a first cancer therapeutic antibody discovery program for Tanabe Research Laboratories USA, Inc. (TRL) and the initiation of a second program.

Under the terms of the collaboration, AvantGen is responsible for generating novel antibodies to specified cancer targets using its proprietary human antibody yeast display technology platform.  TRL has worldwide rights to develop and commercialize antibodies discovered by AvantGen.  AvantGen receives upfront payments and is eligible to receive milestone payments and royalties associated with the development and sale of any products derived from the collaboration.

Read more

 

AvantGen Awarded SBIR Phase II Contract to Develop High-Affinity, Anti-Peptide Rabbit Monoclonal Antibodies for SISCAPA Assays from the NIH/NCI

September 18, 2015

AvantGen, a leader in novel antibody discovery and engineering, in collaboration with SISCAPA Assay Technologies (SAT), was awarded a SBIR Phase II contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide rabbit monoclonal antibodies for mass-spectrometry-based cancer biomarker detection and quantification assays, or so called SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) assays.

Antibodies with high affinity and specificity suitable for cancer biomarker measurements are essential, since there are more than 2,000 potential biomarkers that have been discovered, but only about 100 of them are currently approved by the FDA for clinical diagnostic use.

Read more

 

AvantGen Awarded SBIR Phase II Grant to Develop High-Affinity Rabbit Monoclonal Antibodies for Neuroscience Related Antigens from the NIH/NIDA

March 1, 2015

AvantGen, a leader in novel antibody discovery and engineering, was awarded a SBIR Phase II grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to develop novel rabbit monoclonal neuroscience antibodies against 120 targets. Neuroscience related proteins are highly conservative and homologous among different species, making them difficult targets to generate high quality antibodies.  Therefore, we need novel methods to yield neuroscience antibodies and one that can distinguish between related family members.

Read more